{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:26Z","timestamp":1792784906540,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This work was supported by a grant from Kyung Hee University in 2025.","id":[{"id":"https:\/\/ror.org\/01zqcg218","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41433-026-04697-6","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:07:04Z","timestamp":1782907624000},"page":"2215-2220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and characteristics of newly formed polypoidal lesions in polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"40","author":[{"given":"Jaehwan","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongkyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-5178","authenticated-orcid":false,"given":"Seung-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"4697_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128:443\u201352.","journal-title":"Ophthalmology"},{"key":"4697_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","volume":"15","author":"RF Spaide","year":"1995","unstructured":"Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100\u201310.","journal-title":"Retina"},{"key":"4697_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajo.2020.05.017","volume":"217","author":"K Kim","year":"2020","unstructured":"Kim K, Yang J, Feuer W, Gregori G, Kim ES, Rosenfeld PJ, et al. A comparison study of polypoidal choroidal vasculopathy imaged with indocyanine green angiography and swept-source optical coherence tomography angiography. Am J Ophthalmol. 2020;217:240\u201351.","journal-title":"Am J Ophthalmol"},{"key":"4697_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1167\/iovs.15-18955","volume":"57","author":"M Wang","year":"2016","unstructured":"Wang M, Zhou Y, Gao SS, Liu W, Huang Y, Huang D, et al. Evaluating polypoidal choroidal vasculopathy with optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:526\u201332.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4697_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.oret.2023.11.001","volume":"8","author":"KYC Teo","year":"2024","unstructured":"Teo KYC, Zhao JZ, Klose G, Lee WK, Cheung CMG. Polypoidal choroidal vasculopathy: evaluation based on 3-dimensional reconstruction of OCT angiography. Ophthalmol Retin. 2024;8:98\u2013107.","journal-title":"Ophthalmol Retin"},{"key":"4697_CR6","doi-asserted-by":"crossref","unstructured":"Kimura M, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Kasai Y, et al. Association of polyp regression after loading phase with 12-month outcomes of eyes with polypoidal choroidal vasculopathy. Pharmaceuticals. 2024;17:687.","DOI":"10.3390\/ph17060687"},{"key":"4697_CR7","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4697_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajo.2025.08.007","volume":"280","author":"J Choi","year":"2025","unstructured":"Choi J, Kim K, Lee J, Yu SY. Association between circularity of neovascular lesion and polypoidal lesion regression in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2025;280:79\u201386.","journal-title":"Am J Ophthalmol"},{"key":"4697_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138:935\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4697_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12216-2","volume":"12","author":"A Ito","year":"2022","unstructured":"Ito A, Maruyama-Inoue M, Kitajima Y, Ikeda S, Inoue T, Kadonosono K. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. Sci Rep. 2022;12:7987.","journal-title":"Sci Rep"},{"key":"4697_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100144","volume":"14","author":"P Ruamviboonsuk","year":"2025","unstructured":"Ruamviboonsuk P, Ng DSC, Chaikitmongkol V, Chang A, Chen SJ, Chen Y, et al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS). Asia Pac J Ophthalmol. 2025;14:100144.","journal-title":"Asia Pac J Ophthalmol"},{"key":"4697_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100082","volume":"2","author":"CS Tan","year":"2022","unstructured":"Tan CS, Lim LW, Margaron P. Evolution of polypoidal lesions after treatment of polypoidal choroidal vasculopathy. Ophthalmol Sci. 2022;2:100082.","journal-title":"Ophthalmol Sci"},{"key":"4697_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/jop.2023.0030","volume":"39","author":"HJ Cho","year":"2023","unstructured":"Cho HJ, Kang KH, Yoon W, Lee J, Kim CG, Kim JW. Intravitreal brolucizumab and aflibercept for polypoidal choroidal vasculopathy. J Ocul Pharm Ther. 2023;39:653\u201360.","journal-title":"J Ocul Pharm Ther"},{"key":"4697_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ophtha.2022.09.013","volume":"130","author":"Q Bo","year":"2023","unstructured":"Bo Q, Zhang M, Chen J, Jia H, Shen M, Sun M, et al. Progression of polypoidal lesions associated with exudative recurrence in polypoidal choroidal vasculopathy. Ophthalmology. 2023;130:167\u201378.","journal-title":"Ophthalmology"},{"key":"4697_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.15.5","volume":"62","author":"M Shen","year":"2021","unstructured":"Shen M, Zhou H, Kim K, Bo Q, Lu J, Laiginhas R, et al. Choroidal changes in eyes with polypoidal choroidal vasculopathy after anti-VEGF therapy imaged with swept-source OCT angiography. Invest Ophthalmol Vis Sci. 2021;62:5.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4697_CR16","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina"},{"key":"4697_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92832-w","volume":"15","author":"J Lee","year":"2025","unstructured":"Lee J, Choi J, Yu SY, Kim K. Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment. Sci Rep. 2025;15:8952.","journal-title":"Sci Rep"},{"key":"4697_CR18","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1097\/IAE.0000000000000777","volume":"35","author":"M Inoue","year":"2015","unstructured":"Inoue M, Balaratnasingam C, Freund KB. Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization. Retina. 2015;35:2265\u201374.","journal-title":"Retina"},{"key":"4697_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972","volume":"86","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth U, Reiter GS, Riedl S, Seeb\u00f6ck P, Vogl WD, Blodi BA, et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 2022;86:100972.","journal-title":"Prog Retin Eye Res"},{"key":"4697_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep21090","volume":"6","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep. 2016;6:21090.","journal-title":"Sci Rep"},{"key":"4697_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.oret.2019.09.012","volume":"4","author":"H Zhou","year":"2020","unstructured":"Zhou H, Dai Y, Shi Y, Russell JF, Lyu C, Noorikolouri J, et al. Age-related changes in choroidal thickness and the volume of vessels and stroma using swept-source OCT and fully automated Algorithms. Ophthalmol Retin. 2020;4:204\u201315.","journal-title":"Ophthalmol Retin"},{"key":"4697_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/bjo.86.10.1093","volume":"86","author":"A Okubo","year":"2002","unstructured":"Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol. 2002;86:1093\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4697_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.oret.2025.05.030","volume":"9","author":"C Regillo","year":"2025","unstructured":"Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D\u2019Souza D, et al. TALON phase IIIb study: 32-week primary results of brolucizumab using treat and extend for neovascular age-related macular degeneration. Ophthalmol Retin. 2025;9:1175\u201386.","journal-title":"Ophthalmol Retin"},{"key":"4697_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol. 2021;10:507\u201318.","journal-title":"Asia Pac J Ophthalmol"},{"key":"4697_CR25","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983\u201390.","journal-title":"Eye"},{"key":"4697_CR26","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"4697_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138:935\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4697_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"4697_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4697_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"4697_CR31","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","volume":"40","author":"YC Chang","year":"2020","unstructured":"Chang YC, Cheng CK. Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina. 2020;40:1403\u201311.","journal-title":"Retina"},{"key":"4697_CR32","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1097\/IAE.0000000000002234","volume":"39","author":"E Peiretti","year":"2019","unstructured":"Peiretti E, Iovino C, Sacconi R, Caminiti G, Querques G. Optical coherence tomography angiography characteristics of polypoidal choroidal vasculopathy secondary to chronic central serous chorioretinopathy. Retina. 2019;39:1693\u2013700.","journal-title":"Retina"},{"key":"4697_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-03782-2","volume":"15","author":"K Tanaka","year":"2025","unstructured":"Tanaka K, Onoe H, Takeshima K, Kono M, Wakatsuki Y, Kawamura A, et al. Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. Sci Rep. 2025;15:18975.","journal-title":"Sci Rep"},{"key":"4697_CR34","doi-asserted-by":"crossref","unstructured":"Tan CS, Lim LW, Margaron P. Evolution of Polypoidal lesions after treatment of polypoidal choroidal vasculopathy. Ophthalmol Sci. 2022;2:100082.","DOI":"10.1016\/j.xops.2021.100082"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04697-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:45:39Z","timestamp":1790167539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04697-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":34,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4697"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04697-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}